Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.
Joachim Stoltenborg GranhøjAgnete Witness Præst JensenMario PrestiÖzcan MetInge Marie SvaneMarco DoniaPublished in: Expert opinion on biological therapy (2022)
the sub-population of tumor-reactive TILs) and manufacturing processes. Novel approaches can help overcome current limitations and potentially result in TIL-based ACT entering the mainstream of cancer therapy across tumor types.